Abstract: The present invention provides a liquid pharmaceutical composition comprising a therapeutic agent and an alkoxy-polyethylene glycol, for example, methoxy-polyethylene glycol, for administration of the therapeutic agent to the mammal. The compositions can be applied to a membrane, for example, a nasal membrane during intranasal administration. The invention also provides methods of administering such compositions to a mammal.
Abstract: There is provided a conjugate of a delivery agent containing a chemical moiety and at least one flavonoid. The flavonoid exists in a monomeric form or dimeric form before conjugation and remains in the monomeric form or dimeric form after conjugation. Preferably, the conjugate comprises two flavonoids. The delivery agent is conjugated at the C6 and/or the C8 position of the A ring of the flavonoid. An anti-cancer agent delivery vehicle comprising an anti-cancer agent and the conjugate is also provided.
Type:
Grant
Filed:
March 11, 2011
Date of Patent:
June 27, 2017
Assignee:
Agency for Science, Technology and Research
Inventors:
Motoichi Kurisawa, Kun Liang, Susi Tan, Joo Eun Chung, Jackie Y. Ying
Abstract: The present disclosure is directed in part to methods of treating fibrosis, e.g., hepatic fibrosis and/or intestinal fibrosis, comprising administering to a patient in need thereof an effective amount of a disclosed compound.
Type:
Grant
Filed:
February 8, 2013
Date of Patent:
June 20, 2017
Assignee:
Nogra Pharma Limited
Inventors:
Sergio Baroni, Salvatore Bellinvia, Francesca Viti
Abstract: The present invention relates to polycyclic antiviral compounds, and salts thereof, methods for their preparation and compositions containing them, and the use of the compounds and composition in the treatment of viral infections.
Type:
Grant
Filed:
August 30, 2013
Date of Patent:
June 13, 2017
Assignee:
BIOTA SCIENTIFIC MANAGEMENT PTY LTD
Inventors:
Jeffrey Peter Mitchell, Alistair George Draffan, Vanessa Anne Sanford, Silas Bond, Chin Lim Lim, Penelope Anne Mayes
Abstract: A method of administering non-steroidal-anti-inflammatory drugs, in particular propionic acid derivatives such as ibuprofen, or acetaminophen is provided. This method provides improved therapeutic effect, in particular pain relief, over extended time periods.
Type:
Grant
Filed:
June 9, 2010
Date of Patent:
June 6, 2017
Assignee:
Johnson & Johnson Consumer Inc.
Inventors:
Cathy K. Gelotte, Douglas R. Hough, Gerard P. McNally
Abstract: A multi-layered foil appliqué for decorating nails is cut from a laminated sheet having the following layers: a first adhesive layer residing on a releasable substrate; a base coat residing on the first adhesive layer; a UV-curable adhesive layer residing on the base coat; a foil layer residing on the UV-curable adhesive layer; and a top coat residing on the foil layer. The foil is applied to the UV-curable adhesive layer by contact between the metallic side of a metallized plastic sheet and the adhesive before the adhesive is cured. The bottom coat and top coat are formed from organic solvent-based nail enamels. Sufficient solvent remains in the appliqué to keep it stretchable before use. Residual solvent evaporates after the appliqué is applied to a user's nail.
Abstract: A double colored nail appliqué, method of manufacturing and using, the appliqué having two different decorations sequentially via the user removing the top coat of a second colored enamel layer to expose an underlying base coat with a different, first colored enamel layer. The base coat is covered by a UV adhesive layer that protects it during the removal of the top coat. The nail appliqué may further comprise a metallic foil layer directly above or below the UV layer; a design imprinted on the top or bottom coat of enamel; and, a clear coat of enamel covering the top coat. Removal of the top coat(s) by the user does not damage the underlying coats/layers. Therefore, one nail appliqué can be used to offer two different appearing manicures without having to apply a new nail appliqué.
Abstract: Described are kits, food compositions and methods for cleaning the bowel, e.g., in preparation for a medical procedure, e.g., a diagnostic or treatment procedure, such as an endoscopic or surgical procedure, or radiologic imaging such as CT colography.
Type:
Grant
Filed:
July 9, 2009
Date of Patent:
May 23, 2017
Assignee:
The General Hospital Corporation
Inventors:
Joshua Korzenik, Corey A. Siegel, Douglas Knuth
Abstract: Methods for diagnosis and treatment of endometriosis are described. Methods utilize the recognition that leukocyte miRNAs can be dramatically dysregulated subjects suffering from endometriosis. Accordingly, leukocyte miRNAs, as well as polynucleotides encoding the miRNAs, can be utilized in the diagnosis and treatment of endometriosis.
Type:
Grant
Filed:
March 19, 2015
Date of Patent:
May 16, 2017
Assignee:
University of South Carolina
Inventors:
Mitzi Nagarkatti, Juhua Zhou, Bruce A. Lessey, Prakash Nagarkatti
Abstract: Hydrogels that degrade under appropriate conditions of pH and temperature by virtue of crosslinking compounds that cleave through an elimination reaction are described. The hydrogels may be used for delivery of various agents, such as pharmaceuticals. This invention provides hydrogels that degrade to smaller, soluble components in a non-enzymatic process upon exposure to physiological conditions and to methods to prepare them. The hydrogels are prepared from crosslinking agents that undergo elimination reactions under physiological conditions, thus cleaving the crosslinking agent from the backbone of the hydrogel. The invention also relates to the crosslinking agents themselves and intermediates in forming the hydro gels of the invention. The biodegradable hydro gels prepared according to the methods of the invention may be of use in diverse fields, including biomedical engineering, absorbent materials, and as carriers for drug delivery.
Type:
Grant
Filed:
September 7, 2012
Date of Patent:
May 16, 2017
Assignee:
ProLynx LLC
Inventors:
Gary W. Ashley, Daniel V. Santi, Jeffrey C. Henise
Abstract: An effervescent chewable dosage form that comprises a pH neutralization agent, an acid, and an effervescent agent. The chewable dosage form can also further comprise simethicone, a sweetener, and a lubricant. The pH neutralization agent can be calcium carbonate, the acid can be citric acid and the effervescent agent can be sodium bicarbonate.
Type:
Grant
Filed:
May 19, 2015
Date of Patent:
May 16, 2017
Assignee:
The Procter & Gamble Company
Inventors:
Mark Edward Stella, John Richard Entwisle, Jason William Newlon, Christine Louis Naykki
Abstract: The invention relates to novel pyrrolidine derivatives of formula (I): wherein R1, R2 and R3 are as defined herein, as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water.
Type:
Grant
Filed:
September 23, 2015
Date of Patent:
May 16, 2017
Assignee:
PROBIODRUG AG
Inventors:
Ulrich Heiser, Daniel Ramsbeck, Robert Sommer, Antje Meyer, Torsten Hoffmann, Livia Boehme, Hans-Ulrich Demuth
Abstract: The invention provides compound of the general formula: in which each X independently represents a polymer chain; n represents an integer greater than 1; Q represents a linker; Y represents an amide group; and Z represents either —CH.(CH2L)2 or —C(CH2L)(?CH2), in which each L independently represents a leaving group. The compounds are useful reagents for the conjugation of polymers to proteins, the resulting conjugates being novel and also forming part of the invention.
Abstract: The present invention relates to a method of treating a disorder mediated by soluble adenylyl cyclase in a subject. The method involves administering to a subject an effective amount of a compound disclosed herein that modulates soluble adenylyl cyclase, under conditions effective to treat the disorder mediated by soluble adenylyl cyclase. The present invention also relates to a method of treating a disorder mediated by soluble adenylyl cyclase in a subject, where the disorder is selected from the group consisting of: learning or memory disorders, malaria, fungal infection, spinal cord injury, Alzheimer's disease, amyotrophic lateral sclerosis, and peripheral neuropathy. The method involves modulating soluble adenylyl cyclase in the subject. Another aspect of the present invention relates to a method of modulating soluble adenylyl cyclase. The method involves contacting eukaryotic cells with a compound that modulates soluble adenylyl cyclase, under conditions effective to modulate soluble adenylyl cyclase.
Type:
Grant
Filed:
January 20, 2005
Date of Patent:
May 16, 2017
Assignees:
Cornell Research Foundation, Inc., Kent University
Inventors:
Jochen Buck, Lonny R. Levin, Fritz A. Muhlschlegel
Abstract: Absence epilepsy, a form of epilepsy characterized by nonconvulsive seizures, has proven to be refractive to conventional epilepsy therapies. It has been found that low doses of ganaxolone can be used to reduce absence seizures in subjects with absence epilepsy, particularly pediatric subjects. In addition, ganaxolone therapy is particularly useful in subjects with absence epilepsy characterized by a reduction in tonic inhibition. Low dose ganaxolone is also used to reduce sleep disruptions and to treat sleep disorders in subjects in need of such treatment.
Type:
Grant
Filed:
May 21, 2015
Date of Patent:
April 25, 2017
Assignee:
WISCONSIN ALUMNI RESEARCH FOUNDATION
Inventors:
Mathew Victor Jones, Chiara Cirelli, Kile Patrick Mangan, Aaron B. Nelson
Abstract: A method and pharmaceutical composition are disclosed for treating, ameliorating and/or preventing one or more myocardial disorders in a mammalian heart caused by a myocardial hypoxic event and/or a loss, reduction or interruption in coronary blood flow such as may happen during or after events such as a heart attack, cardiac surgery including coronary artery bypass graft, or coronary artery or myocardial reperfusion. The myocardial disorders include myocardial arrhythmias, myocardial damage and myocardial cell death, and the subsequent loss of haemodynamic function. The myocardial disorders could be in progress or suspected of being in progress at the time of treatment or could be anticipated disorders being treated prophylactically. The method involves the step of administering an effective amount of the composition. The composition comprises as its active ingredient one or more compounds having myocardial persistent sodium channel blocking activity.
Abstract: The present invention relates to methods for prevention and/or treatment of metabolic disorders, post-menopausal obesity and conditions associated with high fat diet consumption including, obesity, body weight gain, fat mass formation, bone mineral content reduction, white adipose tissue weight gain, increased cholesterol levels, increased leptin levels, insulin resistance, type II diabetes, increased blood glucose levels, inflammatory diseases, cardiovascular diseases, fatty liver condition (accumulation of fat in the liver), decreased uncoupling protein-1 (UCP-1) levels and increased lipogenesis.
Type:
Grant
Filed:
May 4, 2010
Date of Patent:
April 18, 2017
Assignee:
GTX, Inc.
Inventors:
Ramesh Narayanan, Muralimohan Yepuru, James T. Dalton
Abstract: The invention discloses a novel quinazoline derivative LU1501 and a preparing method thereof, wherein the quinazoline derivative has a chemical name of N-[(4-fluorophenyl)methyl]-4-N-{7-methoxy-6-[(2-pyrrolidin-1-yl)hydroxyethyl]quinazoline-4-yl}phen-1,4-diamine. The quinazoline derivative and a pharmaceutically acceptable salt, a solvate and a hydrate thereof have excellent anti-tumor activity in vitro and in vivo to MCF-7, SK-BR-3, A549, HCT 116, U-118 MG; U-87 MG and MDA-MB-468, and have preferable application prospects on preparing anti-tumor drugs.
Type:
Grant
Filed:
February 26, 2016
Date of Patent:
April 18, 2017
Assignee:
NANJING GENERAL HOSPITAL OF NANJING MILITARY REGION OF PLA
Abstract: Antibacterial compounds of formula (I) are provided: as well as stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of such compounds.
Type:
Grant
Filed:
March 24, 2014
Date of Patent:
April 11, 2017
Assignee:
Achaogen, Inc.
Inventors:
Heinz E. Moser, Qing Lu, Phillip A. Patten, Dan Wang, Ramesh Kasar, Stephen Kaldor, Brian D. Patterson
Abstract: Erectile dysfunction in a male human patient is ameliorated by oral administration to the patient of a glucocorticoid such as prednisone, prednisolone, cortisone, hydrocortisone, or methylprednisolone and a phosphodiesterase type 5 (PDE5) inhibitor, such as sildenafil, vardenafil, or tadalafil.